// App-Quantinova.ai

: Management (mgmt) of futibatinib-associated adverse events (AEs) in patients (pts) with advanced cancers: Results of a pooled analysis.

Researchers

Presenter

  • Funda Meric-Bernstam

Principal Investigators

  • Antoine Hollebecque

  • Junji Furuse

  • Do-Youn Oh

  • John A. Bridgewater

  • Masashi Shimura

  • Bailey Anderson

  • Nanae Hangai

  • Volker Wacheck

  • Lipika Goyal

Medical Centers

  • Internal Medicine,Seoul National University Hospital ,Seoul,South Koreaļ¼ŒRepublic

  • Department of Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan

  • Taiho Oncology Inc., Princeton, NJ

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Bart's Cancer Institute, London, United Kingdom

  • Gustave Roussy, Villejuif, France

  • Taiho Oncology Inc., Princeton, NJ

  • Massachusetts General Hospital, Boston, MA

Locations

  • United Kingdom

  • Republic of South Korea

  • United States

  • Japan

  • France

Companies

  • Taiho Oncology Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Endocrine/metabolic Diseases (ME)

  • Genetic Disorder

  • Ophthalmology (OP)

Disease

  • Hyperphosphatemia

  • Unspecified Cancer

  • Cataract

  • Microcephaly, epilepsy, and diabetes syndrome

Biomarkers

  • Transthyretin

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • NCT02052778

Sponsors

  • N/A

Result

  • N/A

Copyright Ā© 2026. QuantiNova All rights reserved